Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Philip Morris International (PM) has been under pressure after FDA regulatory action and new tax and product rules in Japan and France, which have introduced near term uncertainty for its smoke free growth story.
See our latest analysis for Philip Morris International.
The recent regulatory hit that knocked roughly 6% off the share price is being reflected in a 30 day share price return of 11.14% and a year to date share price return decline of 1.37%, while the 5 year total shareholder return of 124.15% points to much stronger longer term compounding.
If this kind of regulatory reset has you thinking about where else growth and risk might be priced differently, it could be a good time to scan 20 top founder-led companies
With Philip Morris International now trading at US$158.10 and screens flagging roughly a 23% intrinsic discount, the key question for you is simple: is this regulatory reset creating a genuine buying opportunity, or is the market already pricing in future smoke free growth?
With Philip Morris International closing at $158.10 against a narrative fair value of about $180.38, the current setup hinges on how smoke free growth and profitability assumptions hold up under fresh regulation.
The accelerating global adoption of smoke-free alternatives, driven by increasing health awareness and regulatory moves away from combustibles, is fueling strong double-digit volume and margin growth in PMI’s IQOS, ZYN, and VEEV platforms. This secular shift enables the company to capture new consumer segments, expand its addressable market, and structurally boost net revenues and operating margins over time.
Curious what kind of revenue mix, earnings path, and future P/E the narrative is baking in to reach that fair value gap? The projected growth, margin profile, and valuation multiple assumptions behind this model are far from plain vanilla and worth seeing in full.
Result: Fair Value of $180.38 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this story can shift quickly if regulatory pressure on smoke free products tightens further or if growth in IQOS and ZYN slows against expectations.
Find out about the key risks to this Philip Morris International narrative.
With sentiment split between concerns and optimism, this is a moment to look directly at the data, weigh the trade offs, and act before the narrative moves further. To see how the balance of potential upside and downside stacks up, go through the 5 key rewards and 2 important warning signs
If this kind of pricing reset has you thinking bigger than a single stock, do not sit on the sidelines while other opportunities line up on your screen.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PM.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com